At its meeting of 30 January 2023, the Transparency Council adopted Opinion No. 10/2023 on the legitimacy of amending the reimbursement availability of medicinal products containing the active substance abiraterone acetate and included in the drug programme B.56: “Treatment of patients with castration-resistant prostate cancer (ICD-10 C61)” [and adding it] to the catalogue of reimbursable medicines for chemotherapy.
Publication with the minutes of the Transparency Council meeting